期刊
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
卷 139, 期 7, 页码 2741-2749出版社
AMER CHEMICAL SOC
DOI: 10.1021/jacs.6b12236
关键词
-
资金
- Stand up to Cancer, a joint program of the Entertainment Industry Foundation (EIF)
- American Association for Cancer Research (AACR)
- National Institute for Biomedical Imaging and Bioengineering (NIBIB) [EB008047]
- Koch Institute Core from the NCI [P30-CA14051]
- NIH [P41 EB002503-11]
- Army Research Office [W911NF-13-D-0001]
- Air Force [W911NF-07-D-0004]
The detection of rare circulating tumor cells (CTCs) in the blood of cancer patients has the potential to be a powerful and noninvasive method for examining metastasis, evaluating prognosis, assessing tumor sensitivity to drugs, and monitoring therapeutic outcomes. In this study, we have developed an efficient strategy to isolate CTCs from the blood of breast cancer patients using a microfluidic immune-affinity approach. Additionally, to gain further access to these rare cells for downstream characterization, our strategy allows for easy detachment of the captured CTCs from the substrate without compromising cell viability or the ability to employ next generation RNA sequencing for the identification of specific breast cancer genes. To achieve this, a chemical ligand-exchange reaction was engineered to release cells attached to a gold nanoparticle coating bound to the surface of a herringbone microfluidic chip (NP-(CTC)-C-HB-Chip). Compared to the use of the unmodified (CTC)-C-HB-Chip, our approach provides several advantages, including enhanced capture efficiency and recovery of isolated CTCs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据